Starting with COVID-19 vaccine manufacturing opportunity, the companies plan to expand to other areas including various biosimilars, other vaccines, and diagnostics.
Six months since it was granted emergency approval, Zydus Cadila’s managing director said the company wants to have adequate stock before launching it.
Reuters
Published: 07 Apr 2021 02:43 PM BdST
Updated: 07 Apr 2021 02:43 PM BdST AstraZeneca vaccine against coronavirus disease (COVID-19) is seen in Laakso hospital in Helsinki, Finland Mar 11, 2021. REUTERS
Indian drugmaker Shilpa Medicare Ltd has the capacity to manufacture 100-200 million doses of a protein-based vaccine for COVID-19, a company executive told Reuters on Wednesday. );
}
India, the world s largest vaccine producing nation, has been ramping up the production of COVID-19 vaccines and global firms including AstraZeneca, US-based Novavax and Russia s RDIF have signed manufacturing deals with local players.
RDIF, in particular, has already announced deals with six Indian companies to make more than half a billion doses of its Sputnik-V vaccine, including major drugmaker Dr Reddy s Laboratories and several smaller firms.
3 Min Read
BENGALURU (Reuters) -Indian drugmaker Shilpa Medicare Ltd has the capacity to manufacture 100-200 million doses of a protein-based vaccine for COVID-19, a company executive told Reuters on Wednesday.
Slideshow ( 2 images )
India, the world’s largest vaccine producing nation, has been ramping up the production of COVID-19 vaccines and global firms including AstraZeneca, U.S.-based Novavax and Russia’s RDIF have signed manufacturing deals with local players.
RDIF, in particular, has already announced deals with six Indian companies to make more than half a billion doses of its Sputnik-V vaccine, including major drugmaker Dr Reddy’s Laboratories and several smaller firms.
India s Shilpa Medicare can make 100-200 mln doses of COVID-19 vaccine, says exec leaderpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from leaderpost.com Daily Mail and Mail on Sunday newspapers.